|
US6716452B1
(en)
*
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
|
KR20030046389A
(ko)
*
|
2000-09-01 |
2003-06-12 |
그리폰 테라퓨틱스, 인코포레이티드 |
친핵체에 안정한 티오에스테르 발생 화합물, 제조 및 사용방법
|
|
US8394813B2
(en)
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
|
US7169752B2
(en)
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
|
US20060014697A1
(en)
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
|
AU2002365372A1
(en)
*
|
2001-11-27 |
2003-06-10 |
Astrazeneca Ab |
New process
|
|
TW200400963A
(en)
|
2002-05-21 |
2004-01-16 |
Wyeth Corp |
R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
|
|
AU2003247792B2
(en)
*
|
2002-07-03 |
2009-09-24 |
Nicox S.A. |
Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
|
|
US7244753B2
(en)
*
|
2002-07-29 |
2007-07-17 |
Nitromed, Inc. |
Cyclooxygenase-2 selective inhibitors, compositions and methods of use
|
|
ITMI20021861A1
(it)
*
|
2002-08-29 |
2004-02-29 |
Nicox Sa |
Procedimento di sintesi di nitrossialchilesteri di acidi carbossilici, intermedi impiegabili in detto procedimento e loro preparazione.
|
|
WO2004035037A2
(en)
*
|
2002-10-21 |
2004-04-29 |
Ramot At Tel Aviv University Ltd. |
Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
|
|
AU2005201685B2
(en)
*
|
2002-10-21 |
2008-10-09 |
Ramot At Tel Aviv University Ltd. |
Derivatives of N-Phenylanthranilic Acid and 2-Benzimidazolon as Potassium Channel and/or Cortical Neuron Activity Modulators
|
|
US7632866B2
(en)
|
2002-10-21 |
2009-12-15 |
Ramot At Tel Aviv University |
Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
|
|
AT413944B
(de)
*
|
2003-05-27 |
2006-07-15 |
Binder Eva Dkfm |
Verwendung von oxicam-verbindungen
|
|
CA2527114A1
(en)
*
|
2003-05-30 |
2004-12-16 |
Microbia, Inc. |
Methods for the protection of memory and cognition
|
|
EP1710257A4
(en)
*
|
2004-01-07 |
2011-03-23 |
Seikagaku Kogyo Co Ltd |
HYALURONIC ACID DERIVATIVE AND MEDICAMENT CONTAINING THEREOF
|
|
JP2007532562A
(ja)
|
2004-04-07 |
2007-11-15 |
ザ ユニバーシティ オブ ジョージア リサーチファウンデーション,インコーポレイティド |
グルコサミン、及びグルコサミン/抗炎症薬の相互プロドラッグ、組成物、及び方法
|
|
US8034796B2
(en)
*
|
2004-04-07 |
2011-10-11 |
The University Of Georgia Research Foundation, Inc. |
Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
|
|
JP2005343802A
(ja)
*
|
2004-05-31 |
2005-12-15 |
Norifumi Sakayama |
非ステロイド性消炎鎮痛剤の外用剤を用いた癌細胞の増殖を抑制する方法
|
|
KR100576332B1
(ko)
|
2004-07-16 |
2006-05-03 |
강승우 |
신규한 글라이세리드 유도체 및 이를 포함하는 통증완화용조성물
|
|
US7691364B2
(en)
*
|
2005-01-28 |
2010-04-06 |
Bezwada Biomedical, Llc |
Functionalized drugs and polymers derived therefrom
|
|
WO2006102476A2
(en)
*
|
2005-03-21 |
2006-09-28 |
Vicus Therapeutics Spe 1, Llc |
Compositions and methods for ameliorating cachexia
|
|
US20090117197A1
(en)
*
|
2005-03-21 |
2009-05-07 |
Vicus Therapeutics Llc |
Compositions and methods for ameliorating cachexia
|
|
US8541398B2
(en)
*
|
2005-05-27 |
2013-09-24 |
Antibe Therapeutics Inc. |
Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
|
|
RS53230B
(sr)
*
|
2006-06-27 |
2014-08-29 |
Takeda Pharmaceutical Company Limited |
Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
|
|
US20090238763A1
(en)
|
2006-07-09 |
2009-09-24 |
Chongxi Yu |
High penetration compositions and uses thereof
|
|
US20090221703A1
(en)
|
2006-07-09 |
2009-09-03 |
Chongxi Yu |
High penetration composition and uses thereof
|
|
PT2057139E
(pt)
*
|
2006-07-18 |
2013-12-05 |
Antibe Holdings Inc |
Derivados de sulfureto de hidrogénio de fármacos antiinflamatórios não esteroidais
|
|
US20100221337A1
(en)
*
|
2007-02-14 |
2010-09-02 |
Logical Therapeutics, Inc. |
Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist
|
|
KR20150058566A
(ko)
*
|
2007-06-04 |
2015-05-28 |
테크필즈 인크 |
매우 높은 피부 및 막 침투율을 가지는 nsaia 약물전구체 및 이들의 새로운 의약적 용도
|
|
WO2009012425A2
(en)
*
|
2007-07-19 |
2009-01-22 |
Logigal Therapeutics, Inc. |
Compositions including leukotriene antagonists and nsaids and methods of using the same
|
|
CN101868443A
(zh)
|
2007-09-20 |
2010-10-20 |
特拉维夫大学拉莫特有限公司 |
N-苯基邻氨基苯甲酸衍生物及其用途
|
|
CA2724023C
(en)
*
|
2008-05-13 |
2014-02-18 |
Genmedica Therapeutics Sl |
Salicylate conjugates useful for treating metabolic disorders
|
|
US7662858B2
(en)
|
2008-05-23 |
2010-02-16 |
Aaipharma, Inc. |
Method of treating post-surgical acute pain
|
|
BR122021011394B1
(pt)
|
2008-12-04 |
2021-09-28 |
Chongxi Yu |
Composição de alta penetração de um fármaco principal, e uso de uma hpc
|
|
JP2012520342A
(ja)
*
|
2009-03-16 |
2012-09-06 |
ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ |
代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
|
|
US20100239552A1
(en)
*
|
2009-03-16 |
2010-09-23 |
Genmedica Therapeutics Sl |
Combination Therapies for Treating Metabolic Disorders
|
|
WO2011141341A1
(en)
|
2010-05-14 |
2011-11-17 |
Iberhospitex, S.A. |
Compounds for the synthesis of biostable polyurethane, polyurea or polyurea urethane polymers
|
|
US8466197B2
(en)
|
2010-12-14 |
2013-06-18 |
Genmedica Therapeutics Sl |
Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
|
|
WO2014037832A2
(en)
|
2012-09-06 |
2014-03-13 |
Mahesh Kandula |
Compositions and methods for the treatment of epilepsy and neurological diseases
|
|
CN111012914A
(zh)
|
2012-01-18 |
2020-04-17 |
苏州泰飞尔医药有限公司 |
治疗肺部疾病的高穿透力前药组合物和医药组合物
|
|
WO2013167985A1
(en)
|
2012-05-07 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of neurological disorders
|
|
US9399634B2
(en)
|
2012-05-07 |
2016-07-26 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of depression
|
|
WO2013168021A1
(en)
|
2012-05-07 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
|
|
WO2013168023A1
(en)
|
2012-05-08 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for treatment of parkinson's disease
|
|
US9522884B2
(en)
|
2012-05-08 |
2016-12-20 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of metabolic disorders
|
|
WO2013168025A1
(en)
|
2012-05-08 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for treatment of blood clotting disorders
|
|
US9434704B2
(en)
|
2012-05-08 |
2016-09-06 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurological degenerative disorders
|
|
WO2013167992A1
(en)
|
2012-05-08 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of inflammatory disorders
|
|
WO2013168000A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of severe pain
|
|
WO2013168004A2
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of fibromyalgia pain
|
|
WO2013167997A2
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of metabolic syndrome
|
|
WO2013168002A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of neurological conditions
|
|
WO2013168015A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of asthma and allergy
|
|
US9499527B2
(en)
|
2012-05-10 |
2016-11-22 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of familial amyloid polyneuropathy
|
|
WO2013168012A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of respiratory disorders
|
|
US9273061B2
(en)
|
2012-05-10 |
2016-03-01 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of chronic pain
|
|
WO2013167999A2
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of neurologic diseases
|
|
WO2013168016A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of metabolic syndrome
|
|
WO2013168033A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for treatment of neurologic diseases
|
|
US9321775B2
(en)
|
2012-05-10 |
2016-04-26 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of moderate to severe pain
|
|
WO2013168005A2
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
|
|
NZ701832A
(en)
|
2012-05-23 |
2016-08-26 |
Cellix Bio Private Ltd |
Compositions and methods for treatment of inflammatory bowel disease
|
|
AU2013264820A1
(en)
|
2012-05-23 |
2014-11-27 |
Cellixbio Private Limited |
Compositions and methods for treatment of mucositis
|
|
WO2013175347A2
(en)
|
2012-05-23 |
2013-11-28 |
Mahesh Kandula |
Compositions and methods for the treatment of respiratory disorders
|
|
US9492409B2
(en)
|
2012-05-23 |
2016-11-15 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of local pain
|
|
JP2015518854A
(ja)
|
2012-05-23 |
2015-07-06 |
セリックスビオ プライヴェート リミテッド |
多発性硬化症の治療のための組成物および方法
|
|
WO2013175344A2
(en)
|
2012-05-23 |
2013-11-28 |
Mahesh Kandula |
Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
|
|
US9108942B1
(en)
|
2014-11-05 |
2015-08-18 |
Mahesh Kandula |
Compositions and methods for the treatment of moderate to severe pain
|
|
AU2013285126A1
(en)
*
|
2012-07-03 |
2014-11-27 |
Cellixbio Private Limited |
Compositions and methods for the treatment of moderate to severe pain
|
|
WO2014020480A2
(en)
|
2012-08-03 |
2014-02-06 |
Mahesh Kandula |
Compositions and methods for the treatment migraine and neurologic diseases
|
|
WO2014037833A2
(en)
|
2012-09-06 |
2014-03-13 |
Mahesh Kandula |
Compositions and methods for the treatment inflammation and lipid disorders
|
|
SG11201407325YA
(en)
|
2012-09-08 |
2014-12-30 |
Cellix Bio Private Ltd |
Compositions and methods for treatment of inflammation and lipid disorders
|
|
JP5997658B2
(ja)
*
|
2013-05-08 |
2016-09-28 |
テックフィールズ インコーポレイテッド |
非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用
|
|
US9333187B1
(en)
|
2013-05-15 |
2016-05-10 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of inflammatory bowel disease
|
|
SG11201509782TA
(en)
|
2013-06-04 |
2015-12-30 |
Cellix Bio Private Ltd |
Compositions and methods for the treatment of diabetes and pre-diabetes
|
|
US9096537B1
(en)
|
2014-12-31 |
2015-08-04 |
Mahesh Kandula |
Compositions and methods for the treatment of mucositis
|
|
HRP20220112T1
(hr)
|
2013-12-24 |
2022-04-15 |
Virginia Commonwealth University |
Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre
|
|
NZ736131A
(en)
|
2014-09-26 |
2019-04-26 |
Cellix Bio Private Ltd |
Compositions and methods for the treatment of epilepsy and neurological disorders
|
|
ES2799309T3
(es)
|
2014-09-29 |
2020-12-16 |
Cellix Bio Private Ltd |
Compuestos y composiciones para el tratamiento de esclerosis múltiple
|
|
JP6564868B2
(ja)
|
2014-10-27 |
2019-08-21 |
セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited |
多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの3つの成分の塩
|
|
US9150557B1
(en)
|
2014-11-05 |
2015-10-06 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of hyperglycemia
|
|
US9321716B1
(en)
|
2014-11-05 |
2016-04-26 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of metabolic syndrome
|
|
US9284287B1
(en)
|
2014-11-05 |
2016-03-15 |
Cellix Bio Private Limited |
Compositions and methods for the suppression of carbonic anhydrase activity
|
|
US10208014B2
(en)
|
2014-11-05 |
2019-02-19 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurological disorders
|
|
US9173877B1
(en)
|
2014-11-05 |
2015-11-03 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of local pain
|
|
US9175008B1
(en)
|
2014-11-05 |
2015-11-03 |
Cellix Bio Private Limited |
Prodrugs of anti-platelet agents
|
|
US9290486B1
(en)
|
2014-11-05 |
2016-03-22 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of epilepsy
|
|
WO2016088132A1
(en)
|
2014-12-01 |
2016-06-09 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of multiple sclerosis
|
|
US9206111B1
(en)
|
2014-12-17 |
2015-12-08 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurological diseases
|
|
JP6153264B2
(ja)
*
|
2015-01-05 |
2017-06-28 |
テックフィールズ インコーポレイテッド |
非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用
|
|
SG11201705524SA
(en)
|
2015-01-06 |
2017-08-30 |
Cellix Bio Private Ltd |
Compositions and methods for the treatment of inflammation and pain
|
|
US11325886B2
(en)
|
2016-08-12 |
2022-05-10 |
Oregon Health & Science University |
Amide compounds, pharmaceutical compositions thereof, and methods of using the same
|
|
CN107445872B
(zh)
*
|
2017-09-08 |
2020-04-28 |
四川护理职业学院 |
一种具有潜在脑靶向性的化合物及其制备方法与应用
|
|
US11578032B2
(en)
*
|
2018-02-14 |
2023-02-14 |
Oregon Health & Science University |
Derivatives of sobetirome
|
|
JP6720257B2
(ja)
*
|
2018-09-05 |
2020-07-08 |
テックフィールズ インコーポレイテッド |
非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用
|
|
AU2019397067A1
(en)
|
2018-12-12 |
2021-07-22 |
Autobahn Therapeutics, Inc. |
Novel thyromimetics
|
|
WO2020180624A1
(en)
|
2019-03-01 |
2020-09-10 |
Autobahn Therapeutics, Inc. |
Novel thyromimetics
|
|
US12466781B2
(en)
|
2019-11-29 |
2025-11-11 |
Autobahn Therapeutics, Inc. |
Thyromimetics
|
|
US12590072B2
(en)
|
2020-06-17 |
2026-03-31 |
Autobahn Therapeutics, Inc. |
Thyromimetics
|
|
WO2021257851A1
(en)
|
2020-06-17 |
2021-12-23 |
Autobahn Therapeutics, Inc. |
Thyromimetics
|
|
KR20240131764A
(ko)
*
|
2023-02-24 |
2024-09-02 |
애니머스큐어 주식회사 |
디플루니살 또는 이의 약학적으로 허용가능한 염을 포함하는 암 악액질 치료용 조성물
|
|
WO2025111079A1
(en)
*
|
2023-11-21 |
2025-05-30 |
Medicon Pharmaceuticals, Inc. |
Isomers of phosphosulindac
|
|
CN119431199B
(zh)
*
|
2024-10-24 |
2025-11-18 |
上海凌凯科技股份有限公司 |
一种磺酰胺类化合物的制备方法及中间体
|